STING1 and neoplasm: Thereafter, endogenous adjuvants (including cytosolic DNA) released from dying tumor cells activate the CD103+ subset of DCs to recognize the targeted tumor cells (via DNA-cGAS-STING pathway), following by type I interferon (IFN) generation which in turn recruits DCs and promotes DC translocation into tumor-draining lymph nodes (TDLNs) for the tumor-specific T cell activation [24–27].